NCT06190691View on ClinicalTrials.gov

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions
HealthyHepatic Insufficiency
Interventions
DRUG

Pirtobrutinib

Administered orally

Trial Locations (8)

32132

Riverside Clinical Research, Edgewater

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Miami

33147

Advanced Pharma Clinical Research, Miami

78215

The Texas Liver Institute, San Antonio

78229

Pinnacle Clinical Research, San Antonio

92780

Orange County Research Center, Tustin

92801

Orange County Research Institute, Anaheim

Sponsors

Collaborators (1)

Loxo Oncology, Inc.
All Listed Sponsors
collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT06190691 - Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants | Biotech Hunter | Biotech Hunter